296 related articles for article (PubMed ID: 28786878)
1. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
[TBL] [Abstract][Full Text] [Related]
2. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
3. GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder.
Ellis CL; Chang AG; Cimino-Mathews A; Argani P; Youssef RF; Kapur P; Montgomery EA; Epstein JI
Am J Surg Pathol; 2013 Nov; 37(11):1756-60. PubMed ID: 24061521
[TBL] [Abstract][Full Text] [Related]
4. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
[TBL] [Abstract][Full Text] [Related]
5. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
6. Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers.
Hui Y; Wang Y; Nam G; Fanion J; Sturtevant A; Lombardo KA; Resnick MB
Hum Pathol; 2018 Jul; 77():11-19. PubMed ID: 29317235
[TBL] [Abstract][Full Text] [Related]
7. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
[TBL] [Abstract][Full Text] [Related]
8. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U
Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030
[TBL] [Abstract][Full Text] [Related]
9. Expression of uroplakin II and GATA-3 in bladder cancer mimickers: caveats in the use of a limited panel to determine cell of origin in bladder lesions.
Leivo MZ; Tacha DE; Hansel DE
Hum Pathol; 2021 Jul; 113():28-33. PubMed ID: 33887302
[TBL] [Abstract][Full Text] [Related]
10. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation.
Gopalan A; Sharp DS; Fine SW; Tickoo SK; Herr HW; Reuter VE; Olgac S
Am J Surg Pathol; 2009 May; 33(5):659-68. PubMed ID: 19252435
[TBL] [Abstract][Full Text] [Related]
11. Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell carcinoma, large cell carcinoma, and pleomorphic carcinoma.
Terada T
Int J Clin Exp Pathol; 2013; 6(6):1150-6. PubMed ID: 23696935
[TBL] [Abstract][Full Text] [Related]
12. Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder.
Klopfer K; Delahunt B; Adamson M; Samaratunga H
Anticancer Res; 2014 Nov; 34(11):6779-84. PubMed ID: 25368291
[TBL] [Abstract][Full Text] [Related]
13. [Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases].
Zhang W; Jiang YX; Liu Y; Yu WJ; Zhao H; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):433-7. PubMed ID: 24246859
[TBL] [Abstract][Full Text] [Related]
14. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
15. Uroplakin II Expression in Breast Carcinomas Showing Apocrine Differentiation: Putting Some Emphasis on Invasive Pleomorphic Lobular Carcinoma as a Potential Mimic of Urothelial Carcinoma at Metastatic Sites.
Tajima S; Koda K
Dis Markers; 2016; 2016():2940496. PubMed ID: 27642214
[TBL] [Abstract][Full Text] [Related]
16. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
17. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.
Lopez-Beltran A; Amin MB; Oliveira PS; Montironi R; Algaba F; McKenney JK; de Torres I; Mazerolles C; Wang M; Cheng L
Am J Surg Pathol; 2010 Mar; 34(3):371-6. PubMed ID: 20139762
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
19. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract.
O'Connell FP; Wang HH; Odze RD
Arch Pathol Lab Med; 2005 Mar; 129(3):338-47. PubMed ID: 15737028
[TBL] [Abstract][Full Text] [Related]
20. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
